NPM1 and acute myeloid leukemia: Given the profound impacts of HOXBLINC overexpression on promoting HSC self-renewal and AML initiation, targeted therapeutics could be developed to suppress the overexpressed HOXBLINC lncRNA in NPM1-mutated AML.